GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Yubo International Biotech Ltd (OTCPK:YBGJ) » Definitions » Piotroski F-Score

Yubo International Biotech (Yubo International Biotech) Piotroski F-Score : 4 (As of May. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Yubo International Biotech Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Yubo International Biotech has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Yubo International Biotech's Piotroski F-Score or its related term are showing as below:

YBGJ' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 4
Current: 4

During the past 4 years, the highest Piotroski F-Score of Yubo International Biotech was 4. The lowest was 3. And the median was 4.


Yubo International Biotech Piotroski F-Score Historical Data

The historical data trend for Yubo International Biotech's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yubo International Biotech Piotroski F-Score Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 3.00 4.00

Yubo International Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 2.00 4.00 4.00

Competitive Comparison of Yubo International Biotech's Piotroski F-Score

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yubo International Biotech's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -0.317 + -0.367 + 0.006 + -0.517 = $-1.20 Mil.
Cash Flow from Operations was -0.033 + -0.153 + 0.005 + -0.558 = $-0.74 Mil.
Revenue was 0.157 + 0.001 + 0.429 + 0.022 = $0.61 Mil.
Gross Profit was 0.058 + 0.001 + 0.344 + 0.018 = $0.42 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(2.349 + 2.114 + 1.961 + 1.904 + 1.667) / 5 = $1.999 Mil.
Total Assets at the begining of this year (Dec22) was $2.35 Mil.
Long-Term Debt & Capital Lease Obligation was $0.12 Mil.
Total Current Assets was $0.73 Mil.
Total Current Liabilities was $3.40 Mil.
Net Income was -0.579 + -0.492 + -0.238 + 0.104 = $-1.21 Mil.

Revenue was 0.015 + 0.008 + 0.015 + 0.067 = $0.11 Mil.
Gross Profit was 0.008 + 0.006 + 0.01 + 0.029 = $0.05 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(4.587 + 4.466 + 4.051 + 3.72 + 2.349) / 5 = $3.8346 Mil.
Total Assets at the begining of last year (Dec21) was $4.59 Mil.
Long-Term Debt & Capital Lease Obligation was $0.39 Mil.
Total Current Assets was $0.75 Mil.
Total Current Liabilities was $2.52 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Yubo International Biotech's current Net Income (TTM) was -1.20. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Yubo International Biotech's current Cash Flow from Operations (TTM) was -0.74. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-1.195/2.349
=-0.50872712

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-1.205/4.587
=-0.26269893

Yubo International Biotech's return on assets of this year was -0.50872712. Yubo International Biotech's return on assets of last year was -0.26269893. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Yubo International Biotech's current Net Income (TTM) was -1.20. Yubo International Biotech's current Cash Flow from Operations (TTM) was -0.74. ==> -0.74 > -1.20 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.116/1.999
=0.05802901

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0.39/3.8346
=0.10170552

Yubo International Biotech's gearing of this year was 0.05802901. Yubo International Biotech's gearing of last year was 0.10170552. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=0.725/3.395
=0.21354934

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=0.75/2.523
=0.29726516

Yubo International Biotech's current ratio of this year was 0.21354934. Yubo International Biotech's current ratio of last year was 0.29726516. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Yubo International Biotech's number of shares in issue this year was 119.821. Yubo International Biotech's number of shares in issue last year was 119.815. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.421/0.609
=0.69129721

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.053/0.105
=0.5047619

Yubo International Biotech's gross margin of this year was 0.69129721. Yubo International Biotech's gross margin of last year was 0.5047619. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0.609/2.349
=0.25925926

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0.105/4.587
=0.02289078

Yubo International Biotech's asset turnover of this year was 0.25925926. Yubo International Biotech's asset turnover of last year was 0.02289078. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Yubo International Biotech has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Yubo International Biotech  (OTCPK:YBGJ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Yubo International Biotech Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Yubo International Biotech's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Yubo International Biotech (Yubo International Biotech) Business Description

Traded in Other Exchanges
N/A
Address
31 Xishiku Avenue, Room 105, Building 5, Xicheng District, Beijing, CHN, 100034
Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of nebulizers containing frozen tubes with medical fluid and from the sale of oral liquids health products. The nebulizers are sold directly to consumers on its online e-commerce platform.
Executives
Lina Liu 10 percent owner, officer: CFO, Treasurer and Secretary MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Focus Draw Group Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Boao Biotech Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Flydragon International Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Chinaone Technology Ltd 10 percent owner C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Bai Zhihui director MAGNU-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Jun director, officer: President and CEO MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Yang director MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Jonathan Adereth director C/O MEDIVISION, PO BOX 45 INDUSTRIAL PARK, YOKNEAM ISRAEL
Magna Acquisition Llc 10 percent owner 8000 TOWERS CRESCENT DRIVE, SUITE 1070, VIENNA VA 22182
Kenneth C Riscica officer: Treasurer and Secretary C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Lawrence A Minkoff director, officer: Chairman, President, CSO C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Jerome M Feldman director C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE SUITE 120W, SYOSSET NY 11791
Seymour Kessler director C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE #120W, SYOSSET NY 11791

Yubo International Biotech (Yubo International Biotech) Headlines

No Headlines